



Luxembourg, 21 December 2023

Environmental and Social Completion Sheet (ESCS)¹

Overview

Project Name:	ISA PHARMACEUTICALS (IDFF)
Project Number:	2017-0706
Country:	The Netherlands
Project Description:	<i>The project supported the Company's research and development investments to complete the late stage development (clinical, regulatory, and manufacturing) of ISA101b (a synthetic long peptide (SLP) targeting HPV) in two HPV-induced therapeutic areas i.e. cervical and head and neck cancer.</i>

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

The Promoter's investments that were financed through this operation concern research, development and innovation activities carried out in the pharmaceutical sector, enabling the Company to develop and market its lead development asset ISA101b, a compound to treat HPV-related cancers, as well as to advance other assets in the pipeline. The project activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. Furthermore, the project was carried out in existing facilities already authorised for similar activities and volumes. Therefore, an Environmental Impact Assessment (EIA) was required.

No significant environmental or social issues were noted. The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

Summary opinion of Environmental and Social aspects at completion: *EIB is of the opinion based on reports from the promoter, that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.*

¹ The template is for ILs and FLs